A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
A phase 3 trial of Linvoseltamab, Daratumumab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.
Overview
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) is a phase 3 interventional study registered as NCT07393282 by Regeneron Pharmaceuticals, with 270 participants planned, started 2026-05-21 and due to reach its primary completion in 2033-07-27. Interventions recorded: Linvoseltamab, Daratumumab. Conditions listed: High Risk Smoldering Multiple Myeloma (HR-SMM). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re
Shares Linvoseltamab, Regeneron, Multiple myeloma.
- TrialLINKER-MM1
Shares Linvoseltamab, Multiple myeloma.
- TrialA Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone
Shares Daratumumab, Multiple myeloma.